Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

Taking a look at larazotide
September 2018
SHARING OPTIONS:

RALEIGH, N.C.—A new collaboration is underway between Innovate Biopharmaceuticals Inc. and Dr. O. Colin Stine of the University of Maryland School of Medicine. The focus will be to explore larazotide’s ability to correct dysfunctional intestinal barriers and microbiomes in a number of diseases. Larazotide (INN-202) is being advanced into Phase 3 clinical trials in celiac disease.
 
“Larazotide is the only known molecule in late-stage clinical trials that decreases intestinal permeability,” said Stine. “Permeability of the intestinal barrier and its modulation by the microbiota are fundamental processes underlying several diseases such as environmental enteric dysfunction, known as EED, and autoimmune/inflammatory diseases including celiac disease, non-alcoholic steatohepatitis and inflammatory bowel diseases. Recently, the microbiota and its impact on converting PD1/PDL1 therapy unresponsive tumors sensitive to immunotherapy is opening another key gateway to study the role of the dysfunctional intestinal barrier and its correction by larazotide.”

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2018 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.